{
  "docId": "019dd923-5f69-752d-a9b6-0d0782a66fef",
  "docSlug": "GU7tHQNbAVEJiBcjPEiK",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 9,
  "pageCount": 28,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses a three-column benefit framework to structure the value proposition.",
  "elementsJson": [
    "headline_text",
    "callout_box",
    "icon_grid",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-0d0782a66fef/9",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-0d0782a66fef#slide-9",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "In patients with treatment resistant major depressive disorder (MDD), who have not responded to at least 2 courses of appropriately administered oral antidepressants, a short course of Psilocybin Therapy provides greater and durable efficacy on depressive symptoms, significant improvement of functioning, as well as patient (and caregiver) health-related quality of life and reduced healthcare resource utilisation.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-9d69-7444-a588-faf45830f1eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.66,
        "y": 0.38
      },
      "kind": "list",
      "text": "ECONOMIC BENEFIT: More cost-effective, with reduced healthcare resource utilisation (HRU); Lower hospitalisation rates; Fewer outpatient visits; Delay/prevention of progression to more costly interventions",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65a79a2b-0561-4bd3-b980-237a29eddb4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.06,
        "y": 0.38
      },
      "kind": "list",
      "text": "PATIENT BENEFIT: Faster and longer lasting relief from depressive symptoms; Significant improvement in social, family, & occupational functioning; Convenient experience, with no adherence concerns",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c38f3edb-b6e2-4733-8cbb-6312d907c324",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.36,
        "y": 0.38
      },
      "kind": "list",
      "text": "THERAPEUTIC BENEFIT: Superior efficacy; More sustained/durable efficacy; Safe and well tolerated, with no significant adverse event associated with commonly prescribed antidepressants",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e77f14ce-82b0-40c5-9784-00ea20640958",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Value proposition: In patients with treatment resistant major depressive disorder (MDD), who have not responded to at least 2 courses of appropriately administered oral antidepressants, a short course of Psilocybin Therapy provides greater and durable efficacy on depressive symptoms, significant improvement of functioning, as well as patient (and caregiver) health-related quality of life and reduced healthcare resource utilisation.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8c1bcc9-cd91-4ba6-8c42-c54e3bef91c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. Based on early-stage clinical studies and high level economic analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2bd9be9-8df4-49a0-a2c9-67bcc7551b68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Psilocybin Therapy: Attractive Value Proposition in terms of therapeutic, patient, and economic benefit",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e614282c-2dc4-407d-b661-87950fbb2b0f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "value-proposition",
      "slug": null,
      "matchId": "b055a455-02f2-47d4-9a66-9efb377d9d43",
      "evidence": "Structured as a clear value proposition statement followed by three benefit pillars.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 9,
      "beatId": "0c14e896-3c25-42ed-bf11-05f16b3f5914",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-10 present psilocybin therapy as a solution with significant benefits.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 8,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "5fd4f8fd-e571-4d26-a411-84655b36503b",
      "evidence": "Slides 8-10 discuss the breakthrough therapy designation and its implications for faster access to patients.",
      "position": 1,
      "objective": "Explain why psilocybin therapy is a timely solution",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}